156 related articles for article (PubMed ID: 34059328)
1. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer.
Bao K; Li X; He X; Jian L
Clin Ther; 2021 Jun; 43(6):1107-1115. PubMed ID: 34059328
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Shin S; Park CM; Kwon H; Lee KH
BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.
Nguyen CTT; Petrelli F; Scuri S; Nguyen BT; Grappasonni I
Eur J Health Econ; 2019 Jul; 20(5):763-777. PubMed ID: 30840166
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer.
Wang S; Wen F; Zhang P; Wang X; Li Q
Radiat Oncol; 2019 Jun; 14(1):113. PubMed ID: 31234886
[TBL] [Abstract][Full Text] [Related]
6. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
Leung HW; Chan AL; Muo CH
Clin Ther; 2016 May; 38(5):1174-83. PubMed ID: 27033672
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Mori C; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Aug; 51(9):1416-1422. PubMed ID: 34128055
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System.
Coyle D; Ko YJ; Coyle K; Saluja R; Shah K; Lien K; Lam H; Chan KK
Value Health; 2017 Apr; 20(4):586-592. PubMed ID: 28408000
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
11. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
Miksad RA; Schnipper L; Goldstein M
J Clin Oncol; 2007 Oct; 25(28):4506-7; author reply 4508. PubMed ID: 17906218
[No Abstract] [Full Text] [Related]
12. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
13. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Wen F; Zheng H; Zhang P; Hutton D; Li Q
BMJ Open; 2018 Apr; 8(4):e020128. PubMed ID: 29654023
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
Kumar G; Woods B; Hess LM; Treat J; Boye ME; Bryden P; Winfree KB
Lung Cancer; 2015 Sep; 89(3):294-300. PubMed ID: 26122345
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.
Tam VC; Ko YJ; Mittmann N; Cheung MC; Kumar K; Hassan S; Chan KK
Curr Oncol; 2013 Apr; 20(2):e90-e106. PubMed ID: 23559890
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
19. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
Saif MW
Anticancer Res; 2011 Mar; 31(3):1039-42. PubMed ID: 21498735
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]